Harel Insurance Investments & Financial Services Ltd. reduced its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 41.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 908 shares of the medical research company’s stock after selling 641 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Amgen were worth $158,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in AMGN. FMR LLC increased its stake in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after purchasing an additional 489,720 shares in the last quarter. BlackRock Inc. increased its stake in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after purchasing an additional 909,689 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Amgen by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock worth $1,522,551,000 after purchasing an additional 140,117 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares in the last quarter. 79.53% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on AMGN. ValuEngine cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Barclays reduced their price objective on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research note on Thursday. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 price objective for the company in a research note on Thursday. BidaskClub cut shares of Amgen from a “hold” rating to a “sell” rating in a research note on Saturday, March 24th. Finally, Oppenheimer set a $205.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $190.57.
AMGN stock opened at $168.14 on Friday. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The firm has a market cap of $125,031.95, a price-to-earnings ratio of 13.37, a price-to-earnings-growth ratio of 2.13 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same quarter last year, the business earned $2.89 EPS. Amgen’s revenue for the quarter was down 2.7% compared to the same quarter last year. research analysts anticipate that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a yield of 3.14%. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
Amgen announced that its board has initiated a stock buyback program on Thursday, February 1st that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 4,575 shares of company stock valued at $838,064 in the last quarter. 0.19% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Harel Insurance Investments & Financial Services Ltd. Has $158,000 Stake in Amgen, Inc. (AMGN)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/amgen-inc-amgn-shares-sold-by-harel-insurance-investments-financial-services-ltd.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.